Principia Biopharma Inc., a private, clinical-stage biopharmaceutical company, has generated a pipeline of clinical and preclinical stage molecules for autoimmune/inflammatory diseases and oncology. By utilizing its proprietary Tailored Covalency® technology, the company is revolutionizing the design of oral small molecule therapies for more potent, selective, durable drugs with the goal to enhance the risk benefit profile compared to existing therapies. PRN1008, a reversible covalent BTK inhibitor, is being evaluated in a Phase 2 trial for pemphigus vulgaris, an orphan autoimmune disease. PRN1371, a potent, selective FGFR inhibitor is in a Phase 1 trial for solid tumors. PRN2246, a very potent BTK inhibitor that is able to cross the blood-brain barrier, is completing IND enabling studies. A series of highly selective orally bioavailable immunoproteasome inhibitors round out the company’s portfolio.